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ABSTRACT
Objective: This study was to develop and validate a liquid chromatography–tandem mass spectrometry (LC–MS/MS) for the quantification of 
lenvatinib (LT) in human plasma.
Methods: A simple, sensitive and specific LC–MS/MS method was developed for quantification of LT in human plasma using LTD4 as internal standard 
(IS). The analytical method consists of liquid–liquid extraction of plasma sample followed by the determination of LT by a LC–MS/MS. The analyte was 
separated on a Zorbax Eclipse XDB-C18 (150×4.6 mm, 5 µ) column with an isocratic mobile phase of acetontrile:0.1% formic acid (80:20 v/v) at a 
flow rate of 0.6 mL/minutes. The protonated ions were formed by a turbolon spray in a positive mode were used to detect analyte and IS. The MS/MS 
detection was made by monitoring the fragmentation of m/z 427.10→370.10 for LT and m/z 430.30→370.10 for IS on a MS.
Result: The method was validated with the correlation coefficients of (r2) ≥0.995 over a linear concentration range of 10.20-501.60 pg/mL. This 
method demonstrated intra- and inter-day precision within 1.06-2.42% and 0.03-0.55% and accuracy within 95.64-100.08% and 97.16-100.07%.
Conclusion: This method is suitable and convenient to pharmacokinetics and bioavailability studies for estimation of LT in biological samples by 
LC–MS/MS.
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INTRODUCTION
Lenvatinib (LT) is a multiple receptor tyrosine kinase inhibitor 
indicated for the treatment of thyroid cancer. LT mesylate is chemically 
known as 4-[3-chloro–4-(cyclopropyl carbamoyl amino) phenoxy]-
7-methoxyquinoline–6–carboxamide; methane sulfonic acid (Fig. 1). 
The chemical formula of LT is C21H19ClN4O4, and its molecular weight 
is 426.853 [1-8].
Literature review reveals that very few analytical methods have been 
reported for the determination of LT which includes high-performance 
liquid chromatography (HPLC) [9], LC–mass spectroscopy (MS), [10,11] 
and pharmacokinetics studies [12-15].
From the literature review, it was concluded that the reported 
methods used the lack of deuterated internal standard (IS) using 
HPLC-ESI-MS/MS methods. There is no method reported for estimation 
of LT using deuterated IS in biological samples [16].
The main goal of this study is to develop and validate the novel simple, 
sensitive, selective, rapid, rugged, and reproducible analytical method for 
quantitative determination of LT in human plasma by HPLC-ESI-MS/MS.
MATERIALS AND METHODS
Instrumentation
The Agilent 1200 Series HPLC system (Agilent Technologies, Waldbronn, 
Germany) connected to the API 4000 triple quadrupole instrument 
(ABI-SCIEX, Toronto, Canada) with turbo electrospray interface in 
positive ionization mode was used. Data processing was performed on 
Analyst 1.4.1 software package (SCIEX).
Reagents/materials
LT was obtained from Cadila Pharmaceuticals, India. Lenvatinib-D4 
(LTD4) was procured from ClearSynth, India. Water (HPLC Grade), 
formic acid (analytical grade) was purchased from Merck, Mumbai, 
India. Acetonitrile (HPLC Grade), ethyl acetate, and dichloromethane 
(HPLC grade) were obtained from J.T. Baker, USA. Human plasma was 
procured from Navjeevan Blood Bank, Hyderabad. Milli-Q water was 
taken from the in-house Milli-Q system.
Detection
Detection was done by turbolon spray (API) positive mode with unit 
resolution. Mass transitions were obtained from 427.10→370.10 for LT 
and m/z 430.30→370.10 for LTD4.
Chromatographic conditions
Chromatographic separation was performed using an Xbridge Zorbax 
Eclipse XDB -C18 (150×4.6 mm, 5 µ) at a temperature of 40°C. The mobile 
phase was composed of acetontrile:0.1% formic acid (80:20, v/v) at 
a flow rate of 0.6 mL/minutes. Deuterated LTD4 (IS) was used as the 
appropriate IS in terms of chromatography and extractability. LT and 
LTD4 were eluted at 4.53 minutes, approximately, with a total runtime 
of 8 minutes for each sample.
Preparation of standards and quality control (QC) samples
Standard stock solutions of LT (10.0 mg/mL) and LTD4 (10.0 mg/mL) 
were prepared in acetonitrile. The IS spiking solution (100.0 pg/mL) 
was prepared in mobile phase solution acetonitrile:0.1% formic acid 
(80:20, v/v) from LTD4 stock solution. Standard stock solutions and 
IS spiking solutions were stored in refrigerator conditions of 2-8°C 
until analysis. Standard stock solutions of LT (10.0 mg/mL) were 
added to drug-free screened human plasma to obtain concentration 
levels of 10.2, 20.1, 35.1, 70.2, 100.3, 200.6, 301.2, 401.3, and 
501.6 pg/mL for analytical standards, and 10.2 (lower limit of 
quantification [LLOQ]), 30.1 (lower QC [LQC]), 250.1 (middle QC 
[MQC]) and 461.6 pg/mL (high QC [HQC]) for QC standards, and 
stored in the freezer at 30°C until analysis. The aqueous standards 
were prepared in a mobile phase solution acetonitrile:0.1% formic 
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acid (80:20, v/v) and stored in the refrigerator at 2-8°C until 
analysis.
Biological matrix
Human plasma containing sodium heparin as an anticoagulant was 
used as a biological matrix during method validation. Selectivity and 
sensitivity tests were performed before bulk spiking.
Sample preparation
The LLE method was used to isolate LT and LTD4 from human 
plasma. For this purpose, 50 µL of LTD4 (10 pg/mL) and 200 µL 
of plasma sample were added to the labeled polypropylene tubes 
and vortexed briefly for about 5 minutes. Thereafter, 50 µL of 0.1 M 
NaOH solution and 3 mL of extraction solvent (in the ratio of ethyl 
acetate: dichloromethane 80:20 [v/v]) were added and vortexed for 
about 10 minutes. Next, the samples were centrifuged at 4000 rpm 
for approximately 5 minutes at ambient temperature. From each, a 
supernatant sample was transferred into labeled polypropylene tubes 
and evaporated to a dryness of 40°C briefly, and then reconstituted with 
a mobile phase solution (acetonitrile:0.1% formic acid, 80:20, v/v), and 
the sample was transferred into autosampler vials and injected into the 
LC–MS for study.
Method validation
The validation was performed as per Food and Drug Administration 
guidelines to evaluate the method in terms of linearity response, 
sensitivity, selectivity, precision and accuracy (within-batch and 
between-batch/inter-day), stabilities (freeze-thaw, bench top, short-
term and long-term stock solutions, working solutions, and long-term 
stability in matrix), carryover effects, recovery, dilution integrity, matrix 
effect, matrix factor, autosampler re-injection reproducibility and 
ruggedness experiment [10,16].
System suitability
System suitability experiment was performed by injecting six 
consecutive injections at least once in a day with using aqueous MQC 
solution. System performance experiment was performed by injecting 
a sequence of injections at the beginning of analytical batch and % 
coefficient of variation (CV) was calculated.
Selectivity and sensitivity
Selectivity was performed by analyzing human blank plasma samples 
from six different sources (donors) with an additional hemolyzed group 
and lipedimic group to test for interference at the retention times of 
analytes.
The sensitivity was compared with the LLOQ of the analyte with its 
blank plasma sample. The peak area of blank samples should not be 
<20% of the mean peak area of the LOQ of LT and 5% of the mean peak 
area of LTD4.
Calibration of standard curve (linearity and range)
The linearity of the method was determined using standard plots 
associated with nine-point standard curve including LLOQ and an 
upper limit of quantification (ULOQ). Concentration of calibration 
curve standards was calculated against the calibration curve, and the 
linearity of the method was evaluated by ensuring the acceptance of 
precision and accuracy of calibration curve standards. Two consecutive 
calibration curve standards should not be beyond the acceptance 
criteria. The LLOQ was the lowest concentration at which the precision 
expressed by relative standard deviations (RSD, %CV) is better than 
20% and the accuracy (bias) expressed by a relative difference of the 
measured and true value was also <20%.
Precision and accuracy
The within-run and between-run percentage mean of precision and 
accuracy of the LT were measured by the percent coefficient using six 
replicate samples of variation over the concentration range of LLOQ, 
LQC, MQC, and HQC QC samples for the three precision and accuracy 
batches to their nominal values. The acceptable % coefficient of 
precision and accuracy should be <15%. The between and within batch 
% mean precision and accuracy for LQC, MQC, and HQC samples were 
within the range of 85.00-115.00% and for the LLOQ within the range 
of 80.00-120.00%, respectively.
Recovery
The % mean recoveries were determined by comparing the mean peak 
area of the six replicates of extracted plasma QC samples at high, middle 
1 and 2 and low concentrations against respective mean peak area of 
the six replicates of un-extracted QC samples at high, middle, and low 
concentrations.
A recovery of more than 50% was considered adequate to obtain 
required sensitivity. The % mean IS recovery was determined by 
comparing the mean peak area of IS in the extracted plasma QC samples 
at MQC concentration against the mean peak area of IS in the un-
extracted QC samples at MQC concentration.
Dilution integrity
The dilution integrity of the method was evaluated by diluting the stock 
solution prepared as spiked QC sample at concentration 1.5-2 times 
above the concentration of the highest standard in the calibration 
curve in the screened biological matrix. Conduct dilution integrity 
experiment using six replicates each of diluted QC (1/2) and diluted QC 
(1/10) samples. Process and analyze the diluted QC samples along with 
freshly spiked calibration curve standards and at least two sets of batch 
qualifying QCs (at lower and higher).
Ruggedness
Ruggedness of the method was evaluated using different analyst and 
different column of the same make and model or different equipment of 
the same make and model. The ruggedness experiment should meet the 
acceptance criteria for linearity and intra-batch accuracy and precision.
Matrix effect
To predict the variability of matrix effects in samples from individual 
subjects, matrix effect was quantified by determining the matrix factor, 
which was calculated as follows:
( )
Peak response ratio in presence of extracted matrix 
post extracted
Matrix factor =
Peak response ratio in aqueous standards
Six lots of blank biological matrices were extracted each in triplicates 
and post spiked with the aqueous standard at the mid-QC level, and 
compared with aqueous standards of the same concentration. The 
overall precision of the matrix factor is expressed as %CV and it should 
be <15%.
Stability of LT and LTD4
Short-term stock solution stability
Short-term stock solution stability for LT and IS was performed at 
the stock concentration using six consecutive injections of aqueous 
standard equivalent to ULOQ concentration and working concentration, 
respectively, after storage of at least 6 hrs at ambient temperature. 
Stability was assessed by comparing the stock dilutions of LT and IS 
Fig. 1. Chemical structure of (a) lenvatinib (b) lenvatinib-D4
a b
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prepared from the freshly prepared stock solutions (comparison) 
against stock dilutions of IS prepared from the stock solutions stored at 
ambient temperature (stability). Short-term stock solution stability was 
evaluated by comparing the mean response of stability samples against 
mean response of comparison samples. The precision and accuracy for 
the stability samples must be within ≤15 and ±15%, respectively, of 
their nominal concentrations.
Long-term stock solution stability
Long-term stock solution stability for LT and LTD4 (IS) was performed 
at the stock concentration using six consecutive injections of 
aqueous standard equivalent to ULOQ concentration and working 
concentration, respectively, after storage of at least 4 days in the 
refrigerator at 2-8°C. Stability was assessed by comparing the stock 
dilutions of LT and LTD4 (IS) prepared from the freshly prepared 
stock solutions (comparison) against stock dilutions of LT and LTD4 
(IS) prepared from the stock solutions stored at 2-8°C (stability). 
Long-term stock solution stability was evaluated by comparing the 
mean response of stability samples against mean response ratios of 
comparison samples.
Working solution stability
Short-term stability (at least 6 hrs at ambient temperature) and long-
term stability (at least 4 days at 2-8°C) for working solutions of drug 
(stock solution ULOQ and LLOQ) and IS were performed using six 
consecutive injections of equivalent aqueous standards prepared from 
fresh and stored solutions.
Short-term stability and long-term stability of working solution were 
evaluated by comparing the mean response of stability samples against 
mean response of comparison samples.
Stability of drug in biological matrix
Perform the matrix stability experiment using freshly prepared 
calibration curve standard and three replicates of freshly prepared 
batch qualifying QC samples at HQC and LQC levels. The precision 
and accuracy for the stability samples must be within ≤15 and ±15%, 
respectively, of their nominal concentrations. Stability studies in 
biological matrix were conducted in the various conditions at LQC and 
HQC levels as described below:
Freeze-thaw stability
Freeze-thaw stability of the spiked QC samples was determined after 
first and third freeze-thaw cycles stored at −20±5°C. Six replicates 
of each HQC, and LQC samples were used for assessing each freeze-
thaw experiment (for first and third cycle at both the freezing 
temperatures). The first freeze-thaw cycle was of at least 24 hrs 
followed by a minimum of 12 hrs for subsequent cycles. Process 
and analyze freeze-thaw stability samples along with freshly spiked 
calibration curve and comparison samples (six replicates of each LQC 
and HQC) in screened biological matrix. Evaluate the freeze-thaw 
stability on the basis of % change of LQC and HQC samples. The % 
accuracy and % CV of LQC and HQC should be within ±15.00 and 
≤15.00, respectively.
Bench top stability
Spiked QC samples (six replicates of each LQC and HQC) were stored 
in a deep freezer at temperature −20±5°C, which was retrieved after 
minimum 12 hrs of freezing and was kept at ambient temperature on 
working bench for recommended period of at least 24 hrs. Six replicates 
of each HQC and LQC samples were used for assessing the bench top 
stability experiment. On the completion of recommended period, 
process and analyze bench top stability samples along with freshly 
spiked calibration curve and comparison samples (six replicates of each 
LQC and HQC) in screened biological matrix.
Evaluate the bench top stability on the basis of % accuracy and % CV of 
LQC and HQC samples.
Autosampler re-injection reproducibility
Autosampler re-injection reproducibility was evaluated by re-injecting 
accepted precision and accuracy batch, which were stored preferably 
in either autosampler or in refrigerator for at least 55 hrs or as per 
requirement. Autosampler re-injection reproducibility was evaluated 
by % accuracy and % CV of LQC and HQC samples.
Long-term stability in biological matrix
The long-term stability samples of LQC, MQC, and HQC samples were 
kept frozen in vials at −20±5°C for 40 days were assessed along with 
freshly processed calibration and comparison samples (six samples 
each of LQC, MQC, and HQC). The initial bacterial endotoxins test 
concentration freshly after sample treatment preparation was assumed 
to be 100%. The selection of the stability duration on the basis of the 
characteristic of the analyte(s).
RESULTS AND DISCUSSIONS
Method development
LC–MS/MS has been used as one of the most powerful analytical 
tools in clinical pharmacokinetics for its selectivity, sensitivity, and 
reproducibility. The goal of this work is to develop and validate a 
simple, sensitive, rapid, rugged, and reproducible assay method for the 
quantitative determination of LT from human plasma samples.
Chromatographic conditions, especially the composition and nature 
of the mobile phase, usage of different columns, different extraction 
methods such as solid phase, precipitation, and liquid-liquid 
extraction methods were optimized through several trials to achieve 
the best resolution and increase the signal of LT and LTD4. The MS 
optimization was performed by direct infusion of solutions of both LT 
and LTD4 into the ESI source of the MS. The critical parameters in the 
ESI source include the needle (ESI) voltage, capillary voltage, source 
temperature, and other parameters such as nebulizer gas, heater 
gas, and desolvation gases were optimized to obtain a better spray 
shape, resulting in better ionization of the protonated ionic LT and 
LTD4 molecules. Product ion spectrum for LT and LTD4 yielded high-
abundance fragment ions of m/z 370.10 and m/z 370.10, respectively 
(Figs. 2 and 3). After MS parameters optimized, chromatographic 
conditions such as mobile phase optimization, column optimization, 
and extraction method optimization were performed to obtain a fast 
and selective LC method. A good separation and elution were achieved 
using acetonitrile:0.1% formic acid (80:20, v/v) as the mobile phase, 
at a flow-rate of 0.6 mL/minutes, and injection volume of 10 µL. 
Zorbax Eclipse XDB-C18 (150×4.6 mm, 5 µ) column and liquid-liquid 




System performance experiment was performed by injecting six 
consecutive injections at the beginning of the analytical batch. % CV 
was 3.52.
Carryover test
For carryover test, two samples of the upper LOQ (ULOQ) and four 
samples of blank plasma were processed. These samples were injected 
in the following sequence.
a. 2 blank samples
b. 2 ULOQ samples
c. 2 blank samples.
The step (b) and (c) were repeated 2 times. The results demonstrate 
that there was no interference from the previous injection.
Selectivity and specificity
The analysis of LT and LTD4 using multiple reaction monitoring 
function was highly selective with no interfering compound. 
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Chromatograms obtained from plasma spiked with LT (10.2 pg/mL) 
and LTD4 (100 pg/mL).
Limit of detection (LOD) and LOQ
The limit of detection was used to determine the instrument detection 
levels for LT even at low concentrations. 5 µL of a 0.5 pg/mL solution 
was injected and estimated LOD was 2.5pg/ml with S/N values ≥3-5. 
The LOQ for this method was proved as the lowest concentration of the 
calibration curve which was proved as 0.5 pg/ml.
Calibration curve standards, precision, and accuracy
Calibration curves were plotted as the peak area ratio (LT/LTD4) 
versus (LT) concentration. Calibration was found to be linear over 
the concentration range of 10.2-501.60 pg/mL. The CV% was <5% 
and the accuracy ranged from 85% to 102%. The determination 
coefficients (r2) were >0.9995 for all curves (Table 1). As shown in 
Table 2, the intra-batch CV% was <5% and the accuracy ranged from 
98% to 101.0%. The inter-batch CV% was <5% and the accuracy ranged 
from 98.0% to 101.3%. These results indicate the adequate reliability 
and reproducibility of this method within the analytical range.
Recovery
The recovery following the sample preparation using liquid-liquid 
extraction with methyl tertiary butyl ether was calculated by comparing 
the peak area of LT in plasma samples with the peak area of solvent 
samples and was estimated at control levels of LT. The recovery of LT 
was determined at three different concentrations 30.1, 250.10, and 
461.10 pg/mL, was found as 83.81, 93.08, and 94.53%, respectively 
(Table 3). The overall average recovery of LT and LTD4 was found to be 
90.48 and 85.51%, respectively.
Matrix effect
Six lots of blank biological matrices were extracted each in triplicates 
and post spiked with the aqueous standard at the mid-QC level, and 
compared with neat standards of same concentration in alternate 
injections. The overall precision of the matrix factor is 10.13 for LT. 
There was no ion suppression and ion enhancement effect observed 
due to IS and analyte at respective retention time.
Short-term stock solution stability
Short-term stock solution stability at room temperature
Stock solution each of LT and IS was stable after approximately 9 hrs 
and 30 minutes at room temperature. For LT and LTD4 (IS) the % 
accuracy was 100.21and 101.00, respectively.
Fig. 2: Mass fragmentation pattern of lenvatinib







% CV (n=5) % accuracy
10.20 8.651±2.1 1.1 86.506
20.10 17.099±7.5 2.6 85.072
35.10 34.109±0.9 1.7 97.177
70.23 69.937±1 1.5 99.625
100.32 102.283±2.7 2.8 101.921
200.60 204.666±1.9 3.6 102.093
301.20 304.057±0.7 3.2 101.015
401.31 401.807±0.4 3.2 100.126
501.61 497.59±1.4 2.7 99.201
Values are expressed as (mean±SD) (n=6). SD: Standard deviation, 
CV: Coefficient of variation
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Short-term stock solution stability at refrigerator (2-8°C)
Stock solution each of LT and IS was stable after approximately 9 hrs 
and 30 minutes at refrigerated temperature 2-8°C. For LTD4 (IS) the % 
accuracy was 101.00.
Stability (freeze-thaw, autosampler, bench top, long term)
Quantification of the LT in plasma subjected to three freeze-thaw 
(−30°C to room temperature) cycles shows the stability of the analyte. 
Fig. 3: Mass fragmentation pattern of lenvatinib-D4
The % accuracy ranged from 100.58% to 105.42% of the theoretical 
values. No significant degradation of the LT was observed even after 
55 hrs storage period in the autosampler tray, and the % accuracy ranged 
from 100.96% to 104.77% of the theoretical values. No significant 
degradation of the LT was observed even after 24 hrs storage period 
in the room temperature, and the % accuracy ranged from 100.81% to 
100.91% of the theoretical values. In addition, the long-term stability of 
LT in QC samples after 40 days of storage at −20°C was also evaluated. 
Fig. 4: Representative chromatograms in plasma sample (a) chromatogram of lenvatinib (b) chromatogram of lenvatinib-D4
a b
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The concentrations ranged from 99.67% to 100.56% of the theoretical 
values. These results confirmed the stability of LT in human plasma for 
at least 40 days at −20°C (Table 4).
CONCLUSION
The LC–MS/MS validated method has proved to be very simple, 
sensitive and reliable and successfully applied for the pharmacokinetic 
study in human plasma. The assay method is specific due to the inherent 
selectivity of tandem MS. The major advantage of this method is the 
use of deuterated LTD4 as an IS. The run time is within 8 minutes, and 
only 0.200 mL of plasma was required for each determination of LT, and 
thus the stress to volunteers or patients in clinical studies were greatly 
reduced. This method is suitable and convenient to pharmacokinetics 
and bioavailability studies for estimation of LT in biological samples by 
LC–MS/MS.
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